文献速递慢性肾脏病肾小球疾病

狼疮性肾炎患者CKD G3-5的患病率、进展及危险因素

Chronic kidney disease G3-5 in lupus nephritis-prevalence, progression, and risk factors.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

该回顾性研究纳入183例中国活检证实的狼疮性肾炎患者,平均随访19.9年。34.4%进展至CKD G3-5,9.8%发生肾衰竭,14.2%死亡。治疗1年后eGFR<80 ml/min/1.73 m2和≥2次肾炎复发是CKD G3-5的显著预测因素,而吗替麦考酚酯联合糖皮质激素持续诱导-维持治疗与10年CKD G3-5风险降低相关。

要点

  • 狼疮性肾炎患者10年随访时CKD G3-5患病率约20.8%,平均随访19.9年达34.4%。
  • 治疗1年后eGFR<80 ml/min/1.73 m2和≥2次肾炎复发是CKD G3-5的重要预测因素。
  • 吗替麦考酚酯联合糖皮质激素持续诱导-维持治疗与10年CKD G3-5风险降低相关。

核心结论

  • 狼疮性肾炎患者中CKD G3-5常见,随访10年时约五分之一患者受累。
  • 治疗1年后eGFR<80 ml/min/1.73 m2和≥2次肾炎复发是CKD G3-5及不良临床结局的重要危险因素。
  • 吗替麦考酚酯联合糖皮质激素诱导-维持治疗与随访期间CKD G3-5风险降低相关。

研究设计与样本

  • 回顾性研究,纳入1981-2017年诊断为活检证实的狼疮性肾炎的中国患者183例。
  • CKD G3-5定义为eGFR<60 ml/min/m2持续>3个月。
  • 采用多因素logistic回归确定CKD进展和不良结局的危险因素。

主要发现

  • 平均随访19.9±9.7年,34.4%(63例)发生CKD G3-5,9.8%发生肾衰竭,14.2%死亡。
  • CKD G3-5与初诊时年龄较大、肾功能受损和高血压以及肾炎复发相关。
  • 初诊时eGFR<60 ml/min/1.73 m2者占24.6%,治疗6和12个月后降至13.6%和12%,随访2、5、10年后逐渐升至15.3%、16.4%和20.8%。
  • 多因素分析显示,治疗1年时eGFR<80 ml/min/1.73 m2 [OR 16.684(95% CI 4.305-64.660),P < .001]和≥2次肾炎复发 [OR 7.237(95% CI 2.041-25.919),P = .002]是CKD G3-5和不良临床结局的显著预测因素。
  • 吗替麦考酚酯联合糖皮质激素持续诱导-维持治疗与10年时CKD G3-5风险降低相关 [OR 0.196(95% CI 0.046-0.835),P = .028]。

临床怎么用

  • 对狼疮性肾炎患者应长期监测肾功能,尤其关注治疗1年后eGFR<80 ml/min/1.73 m2和反复肾炎复发的高危患者。
  • 吗替麦考酚酯联合糖皮质激素持续诱导-维持治疗可能有助于降低远期CKD G3-5风险。

局限性

  • 本研究为回顾性设计,可能存在选择偏倚和信息偏倚。
  • 样本来自中国单中心人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite treatment advances, there are limited data on the development of chronic kidney disease (CKD) in patients with lupus nephritis (LN) on long-term follow up. In this study, we aim to investigate the prevalence of CKD, its progression over time, and associated risk factors in patients with LN. METHODS: We conducted a retrospective study on Chinese patients with biopsy-proven LN diagnosed in 1981-2017. CKD G3-5 was defined according to an estimated glomerular filtration rate (eGFR) of <60 ml/min/m2, for >3 months. Risk factors for CKD progression and adverse outcomes were determined by multivariate logistic regression. RESULTS: In total, 183 patients were included. Over a mean follow up of 19.9 ± 9.7 years, 34.4% (63 patients) developed CKD G3-5, 9.8% developed kidney failure (KF) and 14.2% died. CKD G3-5 was associated with older age, renal impairment and hypertension at presentation, and the occurrence of nephritis flares. eGFR <60 ml/min/1.73 m2 was present in 24.6% of patients at presentation, and the prevalence decreased to 13.6% and 12% after 6 and 12 months of treatment, respectively, followed by a gradual increase to 15.3%, 16.4%, and 20.8% after 2, 5, and 10 years of follow up, respectively. In multivariate analysis, eGFR <80 ml/min/1.73 m2 at 1 year [OR 16.684 (95% CI 4.305-64.660), P < .001] and ≥2 nephritis flares [OR 7.237 (95% CI 2.041-25.919), P = .002] were significant predictors of CKD G3-5 development and adverse clinical outcomes during follow up. Continuous induction-maintenance treatment with mycophenolate and glucocorticoid was associated with reduced risk of CKD G3-5 at 10-years [OR 0.196 (95% CI 0.046-0.835), P = .028]. CONCLUSION: CKD G3-5 is common, affecting approximately one-fifth of LN patients after 10 years of follow up. eGFR <80 ml/min/1.73 m2 at 1 year after treatment for active LN and ≥2 nephritis flares are important risk factors, while mycophenolate and glucocorticoid induction-maintenance treatment regimen was associated with a reduced risk of CKD G3-5 during follow up.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Teoh STY, Yap DYH, Tang CSO, et al. Chronic kidney disease G3-5 in lupus nephritis-prevalence, progression, and risk factors. Nephrol Dial Transplant. 2026. PMID: 41042238. doi:10.1093/ndt/gfaf201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。